Implications of staging in lung cancer
- PMID: 9337297
- DOI: 10.1378/chest.112.4_supplement.242s
Implications of staging in lung cancer
Abstract
Lung cancer staging, based on anatomic extent of disease and described by the TNM staging system (T, primary tumor; N, regional lymph nodes; M, distant metastasis), is an important parameter for determining the clinical course of this disease. To evaluate the prognostic importance of TNM staging for lung cancer, we conducted a retrospective study analyzing survival rates according to TNM staging in 2,382 patients who had pulmonary resection for non-small cell lung cancer. Postoperatively, 3 patients were classified in stage 0, 796 in stage I, 304 in stage II, 719 in stage IIIA, 233 in stage IIIB, and 327 in stage IV. The 5-year survival rates for these patients were as follows: stage I, 68.5%; stage II, 46.9%; stage IIIA, 26.1%; stage IIIB, 9.0%; and stage IV, 11.2% (including ipsilateral, intrapulmonary metastases); 5-year survival rates for 140 patients with stage IV disease with intrapulmonary metastases in either the same lobe or another ipsilateral lobe were 17.8% and 8.3%, respectively. There was prognostic significance between stage I and stage II disease, stage II and stage IIIA disease, and stage IIIA and stage IIIB disease, but not between stage IIIB and stage IV disease. Only a few modifications will be required for the TNM staging system, which at present accurately reflects the prognosis of patients with lung cancer and is helpful in determining treatment.
Similar articles
-
Evaluation of TMN classification for lung carcinoma with ipsilateral intrapulmonary metastasis.Ann Thorac Surg. 1999 Aug;68(2):326-30; discussion 331. doi: 10.1016/s0003-4975(99)00465-8. Ann Thorac Surg. 1999. PMID: 10475390
-
Prognosis and survival in resected lung carcinoma based on the new international staging system.J Thorac Cardiovasc Surg. 1988 Sep;96(3):440-7. J Thorac Cardiovasc Surg. 1988. PMID: 2842549
-
[Prognosis after complete surgical resection for non-small cell lung cancer based on the staging classification].Dtsch Med Wochenschr. 2006 Nov 24;131(47):2643-8. doi: 10.1055/s-2006-956268. Dtsch Med Wochenschr. 2006. PMID: 17109272 German.
-
The revised TNM staging system for lung cancer.Ann Thorac Cardiovasc Surg. 2009 Feb;15(1):4-9. Ann Thorac Cardiovasc Surg. 2009. PMID: 19262443 Review.
-
Staging systems of lung cancer.Mayo Clin Proc. 1993 May;68(5):475-82. doi: 10.1016/s0025-6196(12)60197-9. Mayo Clin Proc. 1993. PMID: 8386791 Review.
Cited by
-
c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis.Cancer Sci. 2007 Jul;98(7):1006-13. doi: 10.1111/j.1349-7006.2007.00493.x. Epub 2007 Apr 24. Cancer Sci. 2007. PMID: 17459054 Free PMC article.
-
Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer.J Clin Pathol. 2004 Jun;57(6):591-7. doi: 10.1136/jcp.2003.013508. J Clin Pathol. 2004. PMID: 15166262 Free PMC article.
-
UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon/rectum, and breast): clinical evidence, mechanism of action, and future direction.Surg Today. 2007;37(11):923-43. doi: 10.1007/s00595-007-3578-5. Epub 2007 Oct 25. Surg Today. 2007. PMID: 17952521 Review.
-
Ion channels in lung cancer: biological and clinical relevance.Front Pharmacol. 2023 Oct 24;14:1283623. doi: 10.3389/fphar.2023.1283623. eCollection 2023. Front Pharmacol. 2023. PMID: 37942486 Free PMC article. Review.
-
Expression of EGFR and molecules downstream to PI3K/Akt, Raf-1-MEK-1-MAP (Erk1/2), and JAK (STAT3) pathways in invasive lung adenocarcinomas resected at a single institution.Anal Cell Pathol (Amst). 2014;2014:352925. doi: 10.1155/2014/352925. Epub 2014 Dec 18. Anal Cell Pathol (Amst). 2014. PMID: 25763322 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical